Related references
Note: Only part of the references are listed.Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers
M. Naveed Shaik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration
Justine L. Lam et al.
XENOBIOTICA (2017)
Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
Nagdeep Giri et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
Yosuke Minami et al.
CANCER SCIENCE (2017)
Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use
Gianmauro Numico et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells
Nobuaki Fukushima et al.
CANCER SCIENCE (2016)
GLI2 inhibition abrogates human leukemia stem cell dormancy
Anil Sadarangani et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
Giovanni Martinelli et al.
LANCET HAEMATOLOGY (2015)
A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Andrew J. Wagner et al.
CLINICAL CANCER RESEARCH (2015)
Hedgehog signaling in cancer stem cells: a focus on hematological cancers
Victoria Campbell et al.
STEM CELLS AND CLONING-ADVANCES AND APPLICATIONS (2015)
Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
M. Naveed Shaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened
Michael J. Munchhof et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Share Paper
